Article
Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.
Nature communications - 16 Apr 2018
Andronesi Ovidiu C, Arrillaga-Romany Isabel C, Ly K Ina, Bogner Wolfgang, Ratai Eva M, Reitz Kara, Iafrate A John, Dietrich Jorg, Gerstner Elizabeth R, Chi Andrew S, Rosen Bruce R, Wen Patrick Y, Cahill Daniel P, Batchelor Tracy T
Abstract excerpt
Inhibitors of the mutant isocitrate dehydrogenase 1 (IDH1) entered recently in clinical trials for glioma treatment. Mutant IDH1 produces high levels of 2-hydroxyglurate (2HG), thought to initiate oncogenesis through epigenetic modifications of gene expression. In this study, we show the initial evidence of the pharmacodynamics of a new mutant IDH1 inhibitor in glioma patients, using non-invasive 3D MR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.